Precision BioSciences Files More Lawsuits Against Cellectis Alleging Patent Infringement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Precision BioSciences today announced that it has filed two more patent infringement lawsuits against French firm Cellectis.

The lawsuits were filed in US District Court for the Eastern District of North Carolina and allege Cellectis infringes US Patent Nos. 8,119,381 and 8,119,361. The patents relate to Precision Bio's Directed Nuclease Editor genome engineering technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.